Views & Analysis Ardelyx’s ambition to revolutionise kidney treatment A therapy to treat hyperphosphatemia is moving closer to the market after years of development by California-based company Ardelyx.
News FDA says no to Astellas' geographic atrophy drug Astellas has suffered another major setback with geographic atrophy (GA) treatment Izervay, this time in the US.
Digital Sponsored Decoding physician prescribing behaviour: A data-driven jour... Identifying high-volume prescribers and engaging with key opinion leaders (KOLs) in a target therapeutic area can be a challenge.